Abstract：Although osteosarcoma is the most common malignant bone tumor, its annual incidence is only three per million. Before the 1970s, the prognosis of osteosarcoma was very poor. With the advancement of comprehensive treatments such as chemotherapy, the prognosis of osteosarcoma has been significantly improved. This article attempts to review the development of osteosarcoma treatment in the world, the development of comprehensive treatment in China, the standardization process and the treatment prospects, and hope to present the readers the history and current status of osteosarcoma in China, and the future development as well.
牛晓辉. 中国骨肉瘤综合治疗现状与展望[J]. 中华解剖与临床杂志, 2019, 24(1): 1-5.
Niu Xiaohui. Status and prospect of the combined therapy for osteosarcoma in China. Chinese Journal of Anatomy and Clinics, 2019, 24(1): 1-5.
Chou AJ, Geller DS, Gorlick R. Therapy for osteosarcoma: where do we go from here?[J]. Paediatr Drugs, 2008, 10(5): 315-327. DOI:10.2165/00148581-200810050-00005
[3]
Carter SK. The dilemma of adjuvant chemotherapy for osteogenic sarcoma[J]. Cancer Clin Trials, 1980, 3(1): 29-36
[4]
Evans AE. Mitomycin C[J]. Cancer Chemother Rep, 1961, 14: 1-9
[5]
Sullivan MP, Sutow WW, Taylor G. L-phenylalanine mustard as a treatment for metastatic osteogenic sarcoma in children[J]. J Pediatr, 1963, 63: 227-237. DOI: 10.1016/S0022-3476(63)80333-9
[6]
Sutow WW, Sullivan MP, Wilbur JR, et al. Study of adjuvant chemotherapy in osteogenic sarcoma[J]. J Clin Pharmacol, 1975, 15(7): 530-533. DOI:10.1002/j.1552-4604.1975.tb01476.x
[7]
Cores EP, Holland JF, Wang JJ, et al. Doxorubicin in disseminated osteosarcoma[J]. JAMA, 1972, 221(10): 1132-1138. DOI:10.1001/jama.1972.03200230020005
[8]
Jaffe N. Recent advances in the chemotherapy of metastatic osteogenic sarcoma[J]. Cancer, 1972, 30(6): 1627-1631
[9]
Rosen G, Marcove RC, Caparros B, et al. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery[J]. Cancer, 1979, 43(6): 2163-2177
[10]
Jaffe N, Paed D, Farber S, et al. Favorable response of metastatic osteogenic sarcoma to pulse high-dose methotrexate with citrovorum rescue and radiation therapy[J]. Cancer, 1973, 31(6): 1367-1373
Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma [J]. Clin Orthop Relat Res, 1980(153): 106-120
[15]
Kawaguchi N, Ahmed AR, Matsumoto S, et al. The concept of curative margin in surgery for bone and soft tissue sarcoma[J]. Clin Orthop Relat Res, 2004(419): 165-172
[16]
Jeys LM, Thorne CJ, Parry M, et al. A novel system for the surgical staging of primary high-grade osteosarcoma: the birmingham classification[J]. Clin Orthop Relat Res, 2017, 475(3): 842-850. DOI:10.1007/s11999-016-4851-y
[17]
Navid F, Willert JR, McCarville MB, et al. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma[J]. Cancer, 2008, 113(2): 419-425. DOI:10.1002/cncr.23586
[18]
Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected] [J]. J Clin Oncol, 2007, 25(19): 2755-2763. DOI:10.1200/JCO.2006.10.4117
[19]
Grignani G, Palmerini E, Dileo P, et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study[J]. Ann Oncol, 2012, 23(2): 508-516. DOI:10.1093/annonc/mdr151
[20]
Umeda K, Kato I, Saida S, et al. Pazopanib for second recurrence of osteosarcoma in pediatric patients[J]. Pediatr Int, 2017, 59(8): 937-938. DOI:10.1111/ped.13307.
2019, Vol. 24 
